These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38795314)

  • 21. Quantum Chemical Interaction Analysis between SARS-CoV-2 Main Protease and Ensitrelvir Compared with Its Initial Screening Hit.
    Watanabe C; Tanaka S; Okiyama Y; Yuki H; Ohyama T; Kamisaka K; Takaya D; Fukuzawa K; Honma T
    J Phys Chem Lett; 2023 Apr; 14(15):3609-3620. PubMed ID: 37023394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
    Yang Y; Cao L; Yan M; Zhou J; Yang S; Xu T; Huang S; Li K; Zhou Q; Li G; Zhu Y; Cong F; Zhang H; Guo D; Li Y; Zhang X
    Antiviral Res; 2023 May; 213():105586. PubMed ID: 36997073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
    Kuroda T; Nobori H; Fukao K; Baba K; Matsumoto K; Yoshida S; Tanaka Y; Watari R; Oka R; Kasai Y; Inoue K; Kawashima S; Shimba A; Hayasaki-Kajiwara Y; Tanimura M; Zhang Q; Tachibana Y; Kato T; Shishido T
    J Antimicrob Chemother; 2023 Apr; 78(4):946-952. PubMed ID: 36760083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants.
    Lin M; Zeng X; Duan Y; Yang Z; Ma Y; Yang H; Yang X; Liu X
    Commun Biol; 2023 Jul; 6(1):694. PubMed ID: 37407698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case report: Ensitrelvir for treatment of persistent COVID-19 in lymphoma patients: a report of two cases.
    Furuya C; Yasuda H; Hiki M; Shirane S; Yamana T; Uchimura A; Inano T; Takaku T; Hamano Y; Ando M
    Front Immunol; 2024; 15():1287300. PubMed ID: 38333218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
    Unoh Y; Uehara S; Nakahara K; Nobori H; Yamatsu Y; Yamamoto S; Maruyama Y; Taoda Y; Kasamatsu K; Suto T; Kouki K; Nakahashi A; Kawashima S; Sanaki T; Toba S; Uemura K; Mizutare T; Ando S; Sasaki M; Orba Y; Sawa H; Sato A; Sato T; Kato T; Tachibana Y
    J Med Chem; 2022 May; 65(9):6499-6512. PubMed ID: 35352927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral Nonpeptidic, Noncovalent Triazine Coronavirus Main Protease Inhibitors for Treating COVID-19.
    Chia CSB; Inoue M
    ACS Med Chem Lett; 2022 Sep; 13(9):1394-1396. PubMed ID: 36105344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
    Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
    Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option.
    Ferraro S; Convertino I; Cappello E; Valdiserra G; Bonaso M; Tuccori M
    Expert Opin Drug Discov; 2024; 19(1):9-20. PubMed ID: 37830361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease.
    Noske GD; de Souza Silva E; de Godoy MO; Dolci I; Fernandes RS; Guido RVC; Sjö P; Oliva G; Godoy AS
    J Biol Chem; 2023 Mar; 299(3):103004. PubMed ID: 36775130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2.
    Tyndall JDA
    J Med Chem; 2022 May; 65(9):6496-6498. PubMed ID: 35507419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir.
    Kiso M; Yamayoshi S; Iida S; Furusawa Y; Hirata Y; Uraki R; Imai M; Suzuki T; Kawaoka Y
    Nat Commun; 2023 Jul; 14(1):4231. PubMed ID: 37454219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molnupiravir: First Approval.
    Syed YY
    Drugs; 2022 Mar; 82(4):455-460. PubMed ID: 35184266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.
    Dampalla CS; Zheng J; Perera KD; Wong LR; Meyerholz DK; Nguyen HN; Kashipathy MM; Battaile KP; Lovell S; Kim Y; Perlman S; Groutas WC; Chang KO
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34210738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
    Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K
    EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reconstruction of the unbinding pathways of noncovalent SARS-CoV and SARS-CoV-2 3CLpro inhibitors using unbiased molecular dynamics simulations.
    Noroozi Tiyoula F; Aryapour H
    PLoS One; 2022; 17(2):e0263251. PubMed ID: 35139108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.
    Farhat N; Khan AU
    J Mol Model; 2021 Oct; 27(11):312. PubMed ID: 34601658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highly specific SARS-CoV-2 main protease (M
    Rauch S; Costacurta F; Schöppe H; Peng JY; Bante D; Erisoez EE; Sprenger B; He X; Moghadasi SA; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Wang D; Naschberger A; Dunzendorfer-Matt T; Kaserer T; von Laer D; Heilmann E
    Antiviral Res; 2024 Nov; 231():105969. PubMed ID: 39053514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural basis for the inhibition of coronaviral main proteases by ensitrelvir.
    Lin C; Jiang H; Li W; Zeng P; Zhou X; Zhang J; Li J
    Structure; 2023 Sep; 31(9):1016-1024.e3. PubMed ID: 37421945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.